Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study

Background: Belotecan (Camtobell®, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). Patients and methods: Twenty-seven patients with chemotherapy-naive or c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2008-01, Vol.19 (1), p.123-127
Hauptverfasser:	Lee, D. H., Kim, S.-W., Suh, C., Lee, J.-S., Lee, J. H., Lee, S.-J., Ryoo, B. Y., Park, K., Kim, J. S., Heo, D. S., Kim, N. K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic agents Antineoplastic Agents, Phytogenic - pharmacokinetics Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use belotecan Biological and medical sciences Camptothecin - adverse effects Camptothecin - analogs & derivatives Camptothecin - pharmacokinetics Camptothecin - therapeutic use Carcinoma, Small Cell - drug therapy Disease-Free Survival Female Humans Lung cancer Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Neoplasm Proteins - antagonists & inhibitors Neutropenia - chemically induced Pharmacology. Drug treatments Pneumology Salvage Therapy single agent small-cell lung cancer Topoisomerase I Inhibitors Treatment Outcome Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!